Treatment approaches to reflux oesophagitis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The management of oesophageal reflux disease can and should be highly individualised, depending on the seventy of the disease. Mild occasional symptoms of heartburn can often be controlled with conservative measures or changes in diet and antacids. For patients with erosive or ulcerative oesophageal disease, it is becoming clear that acid plays a crucial role in injury and that suppression of acid enhances healing. Antipeptic dosages of histamine receptor antagonists achieve good relief of symptoms but may not always heal erosive oesophagitis. Healing rates are improved with the use of new hydrogen-potassium adenosine triphosphatase (ATPase) pump inhibitors which suppress virtually all acid production. The recurrence of disease is common after acid suppression therapy is discontinued, suggesting the need for some form of long term maintenance therapy. Promotility drugs, which improve oesophageal motility. have inconsistent results in clinical trials and have been associated with a higher rate of adverse drug effects in comparison with acid-suppressive therapies. Surgical treatment should still be considered for patients with chronic recurrent disease who do not respond well to pharmacological therapies.

Original languageEnglish (US)
Pages (from-to)674-680
Number of pages7
JournalDrugs
Volume39
Issue number5
StatePublished - May 1990

Fingerprint

Peptic Esophagitis
Acids
Esophageal Diseases
H(+)-K(+)-Exchanging ATPase
Therapeutics
Histamine Receptors
Heartburn
Antacids
Esophagitis
Histamine Antagonists
Nutrition
Gastroesophageal Reflux
Pharmaceutical Preparations
Chronic Disease
Clinical Trials
Pumps
Pharmacology
Diet
Recurrence
Wounds and Injuries

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Treatment approaches to reflux oesophagitis. / Lieberman, David.

In: Drugs, Vol. 39, No. 5, 05.1990, p. 674-680.

Research output: Contribution to journalArticle

Lieberman, D 1990, 'Treatment approaches to reflux oesophagitis', Drugs, vol. 39, no. 5, pp. 674-680.
Lieberman, David. / Treatment approaches to reflux oesophagitis. In: Drugs. 1990 ; Vol. 39, No. 5. pp. 674-680.
@article{afa73068bb254ce2b113ed1c27098357,
title = "Treatment approaches to reflux oesophagitis",
abstract = "The management of oesophageal reflux disease can and should be highly individualised, depending on the seventy of the disease. Mild occasional symptoms of heartburn can often be controlled with conservative measures or changes in diet and antacids. For patients with erosive or ulcerative oesophageal disease, it is becoming clear that acid plays a crucial role in injury and that suppression of acid enhances healing. Antipeptic dosages of histamine receptor antagonists achieve good relief of symptoms but may not always heal erosive oesophagitis. Healing rates are improved with the use of new hydrogen-potassium adenosine triphosphatase (ATPase) pump inhibitors which suppress virtually all acid production. The recurrence of disease is common after acid suppression therapy is discontinued, suggesting the need for some form of long term maintenance therapy. Promotility drugs, which improve oesophageal motility. have inconsistent results in clinical trials and have been associated with a higher rate of adverse drug effects in comparison with acid-suppressive therapies. Surgical treatment should still be considered for patients with chronic recurrent disease who do not respond well to pharmacological therapies.",
author = "David Lieberman",
year = "1990",
month = "5",
language = "English (US)",
volume = "39",
pages = "674--680",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Treatment approaches to reflux oesophagitis

AU - Lieberman, David

PY - 1990/5

Y1 - 1990/5

N2 - The management of oesophageal reflux disease can and should be highly individualised, depending on the seventy of the disease. Mild occasional symptoms of heartburn can often be controlled with conservative measures or changes in diet and antacids. For patients with erosive or ulcerative oesophageal disease, it is becoming clear that acid plays a crucial role in injury and that suppression of acid enhances healing. Antipeptic dosages of histamine receptor antagonists achieve good relief of symptoms but may not always heal erosive oesophagitis. Healing rates are improved with the use of new hydrogen-potassium adenosine triphosphatase (ATPase) pump inhibitors which suppress virtually all acid production. The recurrence of disease is common after acid suppression therapy is discontinued, suggesting the need for some form of long term maintenance therapy. Promotility drugs, which improve oesophageal motility. have inconsistent results in clinical trials and have been associated with a higher rate of adverse drug effects in comparison with acid-suppressive therapies. Surgical treatment should still be considered for patients with chronic recurrent disease who do not respond well to pharmacological therapies.

AB - The management of oesophageal reflux disease can and should be highly individualised, depending on the seventy of the disease. Mild occasional symptoms of heartburn can often be controlled with conservative measures or changes in diet and antacids. For patients with erosive or ulcerative oesophageal disease, it is becoming clear that acid plays a crucial role in injury and that suppression of acid enhances healing. Antipeptic dosages of histamine receptor antagonists achieve good relief of symptoms but may not always heal erosive oesophagitis. Healing rates are improved with the use of new hydrogen-potassium adenosine triphosphatase (ATPase) pump inhibitors which suppress virtually all acid production. The recurrence of disease is common after acid suppression therapy is discontinued, suggesting the need for some form of long term maintenance therapy. Promotility drugs, which improve oesophageal motility. have inconsistent results in clinical trials and have been associated with a higher rate of adverse drug effects in comparison with acid-suppressive therapies. Surgical treatment should still be considered for patients with chronic recurrent disease who do not respond well to pharmacological therapies.

UR - http://www.scopus.com/inward/record.url?scp=0025312868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025312868&partnerID=8YFLogxK

M3 - Article

C2 - 2191848

AN - SCOPUS:0025312868

VL - 39

SP - 674

EP - 680

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 5

ER -